The Rogosin Institute 20th Anniversary Celebration
"Tree of Life Gala"

Honoring Maurice R. Greenberg "Tree of Life" Award

Recognizing John C.L. Wang, M.D., Ph.D. Hope and Humanity Award

Tuesday, September 23, 2003

The University Club
One West Fifty Fourth Street
New York City, New York

Cocktails: 6:30 P.M.
Dinner: 7:30 P.M.
Black Tie

For further information contact RI Development Office - 212-746-1552

Nocturnal Hemodialysis

• Rogosin Kidney Center of The Rogosin Institute is the first center in the metropolitan area to offer patients nocturnal hemodialysis. This type of self care home dialysis offers patients independence and freedom for day time activities.
• The procedure is performed six nights a week for seven to eight hours while the patient sleeps. It provides a very gentle, slow, stable hemodialysis treatment.
• With nocturnal hemodialysis, blood pressure is often normal with no medication, anemia is better needing less treatment with Epogen, diets and fluids are not restricted, sleep patterns return to normal and the patient's general sense of well being is increased.
• Nocturnal hemodialysis was developed because of the need to treat patients who cannot get to centers for the conventional three times a week hemodialysis.
• Nocturnal hemodialysis in the home is possible not only because of improvements in dialysis machines and dialyzers but also because of the development of remote control monitoring. RI has developed its own sophisticated monitoring system.
• The patient is ready for home treatment after six to eight weeks of training at The Rogosin Institute Manhattan Dialysis Center.

For more information:

Patients Contact:
Iris Solana, RN 212-746-1425

Physicians Contact:
Jonathan Lorch, M.D. 212-746-1559

 
GlaxoSmithKline And Sepsicure In Licensing Agreement On Compound For Treating Sepsis

LONDON and NEW YORK, 22 February, 2001 --- GlaxoSmithKline plc and Sepsicure ,L.L.C. today announced that they have reached a licensing agreement on a compound for the treatment of sepsis, the often fatal result of severe bacterial infections. The compound is about to enter Phase II clinical studies.

Under terms of the agreement, GlaxoSmithKline will assume responsibility for the continuing development of the compound and gain worldwide marketing rights. Sepsicure, a company formed by The Rogosin Institute (Rogosin) and an affiliate of Metromedia Company, will receive an upfront fee and be entitled to further milestone payments as well as royalties on sales.

The compound, to be called GR 270773 while in development, is a lipid emulsion derived from a research program of Rogosin and Sepsicure. It is designed to bind and remove a bacterial toxin called endotoxin, the most common trigger of the complex series of biochemical and physiologic events leading to sepsis. Endotoxin is released into the bloodstream by bacteria in infected tissue; endotoxin is also produced by bacteria in the large bowel and can enter the blood when the protective barrier of the bowel is compromised by infection, other medical emergencies, or surgery. Endotoxin can than activate pathways of inflammation and blood-clotting, leading to severe sepsis, septic shock, multiple-organ failure, and death.

"Severe sepsis remains one of the leading causes of death in intensive-care units, a syndrome that cried out for new therapeutic approached," said Dr. Tadataka Yamada, Chairman, Research and Development, GlaxoSmithKline. "We are eager to take forward the innovative work already done by Rogosin to meet this clear medical need.

Time Magazine Article